Insights from 2023 ASCO® Annual Meeting


 

ASCO® 2023 Insights: "Discussion of LBA4619, Phase 3 THOR Study - Results of Erdafitinib vs. Chemo in Advanced/Metastatic UC With Select FGFR Alterations (The Emerging Role of Targeted Therapy)"

89 views
July 1, 2023
Comments 0
Login to view comments. Click here to Login